11 completed, 3 terminated, 3 unknown, 1 active not recruiting. 19 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 11, Terminated 3, Unknown 3, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 2 | Unknown 1, Withdrawn 1 |
Follow ambrisentan: new trials by email Literature Review of ambrisentan trials Research Report on ambrisentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome Ambrisentan, Terlipressin - Hepatorenal Syndrome, Liver Cirrhosis | Phase 2 | Active not recruiting | Noorik Biopharmaceuticals AG | 54 | 2024-04-17 | 2026-04-13 |
| A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19 Ambrisentan, Placebo - Covid19, Hypoxemia | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 88 | 2021-02-08 | 2023-03-21 |
| Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension Sulfasalazine, Ambrisentan, Sulfasalazine's placebo - Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 80 | 2020-08-01 | 2020-08-27 |
| mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms EDP1815, Dapagliflozin, Ambrisentan - COVID-19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 454 | 2020-07-03 | 2023-07-28 |
| A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis Ambrisentan - Cirrhosis, Portal Hypertension | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 19 | 2019-04-11 | 2021-02-26 |
| Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery Ambrisentan 10 MG - Kidney Failure, Acute | Phase 2 | Unknown | Bnai Zion Medical Center | 30 | 2018-10-11 | 2020-06-29 |
| Ambrisentan in Single Ventricle Ambrisentan, Placebo - Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex | Phase 2 | Completed | Kevin Hill | 16 | 2015-07-01 | 2019-09-12 |
| Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Ambrisentan, Placebo - Systemic Sclerosis, Pulmonary Hypertension | Phase 2 | Completed | Heidelberg University | 38 | 2014-07-01 | 2020-04-30 |
| Drug Combination on Exercise Performance at High Altitude ambrisentan and theophylline, placebo - Acute Mountain Sickness | Phase 2 / Phase 3 | Completed | University of Montana | 28 | 2013-08-01 | 2016-02-26 |
| Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma Ambrisentan, Bosentan, Placebo - Asthma | Phase 2 | Unknown | University of Glasgow | 18 | 2012-11-01 | 2012-06-12 |
| Ambrisentan for Treatment of Portopulmonary Hypertension ambrisentan - Portopulmonary Hypertension | Phase 1 / Phase 2 | Withdrawn | Medical University of Graz | 2012-07-01 | 2016-06-17 | |
| Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 Ambrisentan - Hypertension, Pulmonary | Phase 2 | Completed | GlaxoSmithKline | 38 | 2011-06-21 | 2022-12-30 |
| Efficacy and Safety of Ambrisentan in Children 8-18yrs Ambrisentan - low dose, Ambrisentan - high dose - Hypertension, Pulmonary | Phase 2 | Terminated | GlaxoSmithKline | 41 | 2011-01-04 | 2019-10-08 |
| Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration Bosentan, Ambrisentan, Placebo - Pulmonary Hypertension | Phase 2 / Phase 3 | Completed | Center for Health Sciences, Serbia | 30 | 2011-01-01 | 2013-05-08 |
| Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Ambrisentan - Sarcoidosis, Pulmonary Hypertension | Phase 2 / Phase 3 | Completed | Medical University of South Carolina | 16 | 2008-11-01 | 2018-08-02 |
| Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension GSK1325760A - Hypertension, Pulmonary | Phase 2 | Completed | GlaxoSmithKline | 25 | 2007-08-01 | 2012-10-15 |
| Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension ambrisentan - Pulmonary Hypertension | Phase 2 | Completed | Gilead Sciences | 36 | 2005-05-01 | 2013-06-17 |
| Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension ambrisentan - Pulmonary Hypertension | Phase 2 | Completed | Gilead Sciences | 54 | 2003-04-01 | 2012-01-27 |
| Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension BSF 208075 - Pulmonary Hypertension | Phase 2 | Completed | Gilead Sciences | 60 | 2002-09-01 | 2009-04-16 |
Hypertension, Pulmonary (9) · Pulmonary Arterial Hypertension (5) · Acute Kidney Injury (2) · COVID-19 (2) · Altitude Sickness (1) · Ascites (1) · Asthma (1) · Baetz-Greenwalt syndrome (1) · Dyspnea (1) · Esophageal and Gastric Varices (1) · Familial Primary Pulmonary Hypertension (1) · Fibrosis (1) · Hepatitis B (1) · Hepatitis C (1) · Hepatorenal Syndrome (1)
Gilead Sciences (3) · GlaxoSmithKline (3) · Noorik Biopharmaceuticals AG (3) · Bnai Zion Medical Center (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Center for Health Sciences, Serbia (1) · Heidelberg University (1) · Kevin Hill (1) · Medical University of Graz (1) · Medical University of South Carolina (1) · RenJi Hospital (1) · University of Glasgow (1) · University of Montana (1)
United States (6) · Germany (4) · Spain (4) · France (3) · Italy (3) · Japan (3) · Argentina (2) · Hungary (2) · Russia (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · China (1) · Croatia (1)
Don C Rockey, MD (1) · Horst Olschewski, MD (1) · Iker Navarro, MD (1) · Jieyan Shen, PhD (1) · Joseph Cheriyan, MBChB MA FRCP (1) · Kevin Hill, MD (1) · Lewis Rubin, MD (1) · Marc A Judson, MD (1) · Mark Spears, MBChB PhD (1) · Ofir Avitan, M.D. (1) · Rok Civljak, MD (1) · Rudolf E. Stauber, MD (1) · Sergej M Ostojic, MD, PhD (1)
PMID 18812445, PMID 24342407, PMID 31655622, PMID 32736592, PMID 34473343, PMID 36579617, PMID 37332660
2018 (1)